Back

JPP · Lens · Cyclophosphamide and epirubicin-induced diabetes mellitus in breast cancer: A rare occurrence

PDF

Article · Volume 7, Issue 3 · pp. 146–148

Cyclophosphamide and epirubicin-induced diabetes mellitus in breast cancer: A rare occurrence

Pramod Kumar Sharma1, Arup Kumar Misra1, Vikram Singh1, Ajay Gupta1, Shrishti Saroha1, Surjit Singh1

  1. 1Departments of Pharmacology and Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.

Abstract

Breast cancer is the leading cause of death in women. Epirubicin and cyclophosphamide (EC) is one of the chemotherapeutic regimens used for the treatment of breast cancer. We describe a case treated with EC regimen and who presented to us with symptoms suggestive of diabetes mellitus postchemotherapy. Absence of family history of diabetes and normal blood sugar level, prechemotherapy points toward drug-induced hyperglycemia. These chemotherapeutic agents capable of altering immune response and might act synergistically to cause immunological damage to the islets of pancreas which might precipitate diabetes mellitus. Causality analysis on Naranjo’s scale indicates a possible association with regimen.

Keywords: Cyclophosphamide; diabetes mellitus; epirubicin; hyperglycemia

The full text of this article is available as a PDF. Open the PDF.